Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium® (SABCS).
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.
The council unites leading scientists, clinicians, and advocates to ensure that cutting-edge research and lived experience together shape the future of mental health care.
inTRAvent Medical, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, proudly announces the appointment of Dr. Adam S. Arthur, MD, MPH, as Chief Clinical Strategy Officer (CCSO).
After 40 years of practice as a pediatric cardiologist, Dr. Jeffrey Towbin will retire from Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center (UTHSC) on June 30, 2025.
Delta Dental of Tennessee (Delta Dental) and its charitable arm, the Smile180 Foundation, recently presented Dr. Rhonda Switzer-Nadasdi, CEO of Interfaith Dental, with its Smile Power Award.
A landmark law recently passed in Tennessee raises awareness about psychotropic drugs linked to potential violent behavior, marking a paradigm shift in advancing public safety and accountability for these prescriptions.
First new American College of Gastroenterology (ACG) Clinical Guideline[1] for H. pylori infection since Talicia’s approval lists Talicia as an empirically prescribed first-line option.
